Opus Genetics, INC 8-K filings

Opus Genetics announced Q2 2026 financial results, highlighting progress in gene therapy programs for inherited retinal diseases, with key data expected soon and cash runway extending into 2029.

Opus Genetics highlighted its expanding gene therapy pipeline for inherited retinal diseases (IRDs), with five programs targeting significant unmet needs and multiple clinical data readouts expected.

Opus Genetics provided an update on its gene therapy pipeline, highlighting progress in five Inherited Retinal Disease (IRD) programs and outlining upcoming clinical milestones.

Opus Genetics announced Q1 2026 financial results, highlighting progress in gene therapy programs for inherited retinal diseases and an extended cash runway into 2029.

Opus Genetics, Inc. has successfully closed an initial $35 million tranche of a $155 million senior secured note facility.

Opus Genetics, Inc. held its 2026 annual meeting, where stockholders elected directors, ratified auditor appointment, approved executive compensation, and authorized a stock increase.

Opus Genetics has entered into agreements to reimburse top executives for excise taxes triggered by a potential change in control of the company.

Opus Genetics, Inc. announced a $25.0 million private placement of Series B Non-Voting Convertible Preferred Stock to fund its gene therapy clinical programs and general corporate purposes.

Opus Genetics presented positive clinical data for its LCA5 gene therapy and outlined a robust pipeline targeting a $15 billion market opportunity at the J.P. Morgan Healthcare Conference.

Opus Genetics highlights significant 2025 progress in gene therapy development and outlines key clinical and regulatory catalysts for 2026, supported by a strong cash position.

Opus Genetics' partner, Viatris Inc., has filed a supplemental New Drug Application with the FDA for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia, backed by positive Phase 3 trial results.

Opus Genetics announced its third-quarter 2025 financial results and provided a corporate update highlighting positive clinical data for OPGx-LCA5 and new funding.

Opus Genetics, Inc. announced a registered direct offering of common stock and pre-funded warrants, raising approximately $23.0 million to fund its gene therapy clinical programs.

Opus Genetics announced a $23 million registered direct offering and successful FDA meeting for its OPGx-LCA5 gene therapy, extending its cash runway into H2 2027.

Opus Genetics announced positive three-month pediatric and 18-month adult data from its Phase 1/2 clinical trial for OPGx-LCA5, an investigational gene therapy for Leber congenital amaurosis type 5.

Opus Genetics, Inc. has appointed Robert Gagnon, an experienced biotech executive, as its new Chief Financial Officer, effective September 2, 2025.

Opus Genetics, Inc. announced the closing of a private placement raising approximately $3.5 million to fund manufacturing development for its gene therapy candidates.

Opus Genetics announced positive clinical data, RMAT designation for OPGx-LCA5, and strong Phase 3 results for Phentolamine, extending cash runway into H2 2026.

Opus Genetics, Inc. has entered into a strategic funding and license agreement with the Global RDH12 Alliance to advance its OPGx-RDH12 gene therapy program for inherited childhood blindness, securing up to $1.6 million in funding.

Opus Genetics, Inc. announced positive topline results from its VEGA-3 Phase 3 trial for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia, meeting its primary and key secondary endpoints.

Opus Genetics, Inc. announced the departure of its Chief Financial Officer, Nirav Jhaveri, effective June 25, 2025, and the appointment of Amy Rabourn as interim principal financial and accounting officer.

Opus Genetics announced it has secured up to $2 million in non-dilutive funding from the RD Fund, extending its cash runway into the second half of fiscal year 2026.

Opus Genetics, Inc. has entered into a funding agreement with Foundation Fighting Blindness Retinal Degeneration Fund (RDF) for up to $2,000,000 to advance its MERTK gene therapy program for retinitis pigmentosa.

Opus Genetics reports positive 12-month data from its OPGx-LCA5 Phase 1/2 trial and advances its pipeline with key milestones expected in 2025 and 2026.

Opus Genetics held its annual meeting on April 30, 2025, where stockholders elected directors, ratified the auditor, approved executive compensation on an advisory basis, and approved the conversion of Series A Preferred Stock into common stock.

Opus Genetics terminates its $50 million purchase agreement with Lincoln Park Capital due to unfavorable market conditions.

Opus Genetics reports its full year 2024 financial results, highlighting a transformative year with a strategic acquisition and a strengthened pipeline of gene therapy assets.

Opus Genetics has successfully closed a public offering and private placement, raising approximately $20 million to advance its gene therapy programs.

Opus Genetics reports preliminary unaudited financial results for 2024, projecting a significant net loss and detailing cash usage.

Opus Genetics amends its bylaws to enhance stockholder rights and files a patent infringement lawsuit against Sandoz Inc. regarding RYZUMVI patents.